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Sanger sequenced for antiviral resistance in our reference clinical virology laboratory using 114 6 a nested RT-PCR approach described below ( Figure 1A )(36). To best compare Sanger 115 versus NGS and to limit PCR cycles prior to NGS library preparation for more accurate allelic 314 315 NGS detected more resistance mutations but these did not significantly associate with 316 virological failure, which was more likely attributable to drug non-adherence.
317
Of 69 patients with clinical follow-up, 22 (32%) had low frequency DRMs detected by NGS 318 that were not found by Sanger. Low frequency DRMs were most commonly associated with 319 NRTI resistance (9 patients), followed by NNRTI (7 patients), PI (6 patients), and INSTI (4 320 patients). Five (7%) patients received drugs which would have been contraindicated based 321 on the resistance profiles found by NGS.
322
We were not able to detect a difference in the risk of virologic failure between Figure 5B ). The 388 association may also be confounded by higher viral loads, which could increase the 389 likelihood that a minor variant is present in a sufficient quantity for detection by NGS.
390
However, we think the contribution of this source of confounding is minimal in our study 391 because the laboratory acceptance criteria for the test is 1000 copies/mL and just eight 392 (6%) tests were below this threshold. Furthermore, low frequency variants were detected 393 across a range of viral loads ( Figure S2 ).
394
More than 80% of patients in our cohort were prescribed a regimen that included an while those with improved adherence achieved suppression (below the limit of detection; 403 <40 copies/mL). This suggests that poor adherence may be a primary factor affecting rates 404 of viral suppression in this cohort, irrespective of the prevalence of low frequency DRMs.
405
By evaluating the utility of NGS in the context of a pragmatic patient population, we 406 provide a real-world example of its potential to inform clinical care and elucidate factors 407 that could affect its implementation. Our focus on a single high-resource setting is a 408 potential limitation of the study. Seattle is unique in already having achieved UNAIDS goals 409 of 90% of patients on ARV with suppressed virological loads, indicating a smaller potential 410 return on investment for NGS antiviral testing and a low overall prevalence of antiviral 411 18 resistance. In a high-resource clinical setting, any indication of resistance on a Sanger 412 resistance assay report-even at low levels-is sufficient to rule out that drug for an ARV 413 regimen. DRMs causing any degree of change to the level of resistance interpreted by HIVdb 414 were therefore considered in this analysis. In less resource-rich settings, however, 415 "potential" (level 1) and "low-level" (level 2) resistance may need to be excluded from the 416 analysis because their clinical significance is not well understood and may be overly 417 conservative for prescribing practices in resource-limited settings.
418
Another limitation of our study is its low power. Despite significant efforts exerted 419 to obtain a sufficiently large cohort size for the analysis, more than a third of patients in the 420 test cohort were excluded from the sample cohort due to lack of follow-up (or inability to 421 obtain medical records). The exclusion of these individuals is not a major concern as a 422 source of selection bias because loss to follow-up is a regular occurrence in the course of 
691
RNA level >200 copies/mL at a test date more than one month after baseline.
692
[a] Lamivudine/zidothymidine was replaced with emtricitabine/tenofovir following poor 693 adherence in patient's regimen, potentially contributing to subsequent suppression. 
